Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study-Reference-Cited by-同舟云学术

Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study

Published:2021-10 Issue: Volume:55 Page:103209
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Grytten Nina,Myhr Kjell-Morten,Celius Elisabeth G.,Benjaminsen Espen,Kampman Margitta T.,Midgard Rune,Vatne Anita,Aarseth Jan H.,Riise Trond,Torkildsen Øivind

Funder

Western Norway Regional Health Authority

Helse Vest Regionalt Helseføretak

Merck

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference35 articles.

1. Cancer co-occurrence patterns in Parkinson's disease and multiple sclerosis-Do they mirror immune system imbalances?;Ajdacic-Gross;Cancer Epidemiol.,2016

2. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients;Alping;Ann. Neurol.,2020

3. Cancer risk among patients with multiple sclerosis and their parents;Bahmanyar;Neurology,2009

4. Level of education and multiple sclerosis risk over a 50-year period: registry-based sibling study;Bjornevik;Mult. Scler.,2017

5. Mobility impairments and use of preventive services in women with multiple sclerosis: observational study;Cheng;BMJ,2001

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palliative Care Aspects in Multiple Sclerosis;Journal of Pain and Symptom Management;2024-05

2. Bladder Cancer Diagnosis and Treatment for Patients with Neurogenic Bladder: Does the Literature Support a Different Approach?;Current Bladder Dysfunction Reports;2024-04-02

3. Association between multiple sclerosis and cancer risk: A two-sample Mendelian randomization study;PLOS ONE;2024-03-19

4. The Impact of Aging on Multiple Sclerosis;Current Neurology and Neuroscience Reports;2024-02-28

5. Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies;Neurology;2024-02-27